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A genetic network that suppresses genome
rearrangements in Saccharomyces cerevisiae
and contains defects in cancers
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Gross chromosomal rearrangements (GCRs) play an important role in human diseases,
including cancer. The identity of all Genome Instability Suppressing (GIS) genes is not
currently known. Here multiple Saccharomyces cerevisiae GCR assays and query mutations
were crossed into arrays of mutants to identify progeny with increased GCR rates. One
hundred eighty two GIS genes were identified that suppressed GCR formation. Another 438
cooperatively acting GIS genes were identified that were not GIS genes, but suppressed the
increased genome instability caused by individual query mutations. Analysis of TCGA data
using the human genes predicted to act in GIS pathways revealed that a minimum of 93% of
ovarian and 66% of colorectal cancer cases had defects affecting one or more predicted GIS
gene. These defects included loss-of-function mutations, copy-number changes associated
with reduced expression, and silencing. In contrast, acute myeloid leukaemia cases did not
appear to have defects affecting the predicted GIS genes.
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G
enetic instability is seen in most cancers and is thought to
play a critical role in the development and progression
of tumours1. There are two general types of genetic
instability seen in cancer2: the accumulation of large numbers of
mutations and the accumulation of genome rearrangements such
as translocations, copy-number changes and aneuploidy2,3.
The study of cancer susceptibility syndromes like Fanconi
Anemia and the BRCA1- and BRCA2-defective breast and
ovarian cancer syndromes provided the first evidence for a
causal link between defects causing increased genome
rearrangements and the development of cancer4,5. However,
this understanding is incomplete in part because most relevant
studies have focused on a limited number of genes and the lack of
genetic screens to identify Genome Instability Suppressing (GIS)
genes in mammalian cells.
Due to the availability of quantitative genetic assays that
can detect gross chromosomal rearrangements (GCRs), genetic
studies in Saccharomyces cerevisiae have provided considerable
information about the spontaneous formation of genome
rearrangements6–11. The observed GCRs depend in part on the
features of the specific GCR assay but include (1) terminal
deletions healed by de novo telomere addition, (2) monocentric
translocations, (3) interstitial deletions and (4) complex
GCRs resulting from multiple cycles of rearrangement
secondary to the formation of dicentric chromosomes by
multiple processes6,7,12–17. Overall, the GCRs observed parallel
to those being identified by whole-genome analysis in human
diseases including cancer. In addition, GCR assays have been used
to identify genes that prevent GCRs from occurring and genes
that act in the formation of GCRs6–10,15,18–27.
Even in S. cerevisiae, our knowledge of GIS genes is
incomplete. This is in part because most known GIS genes
have been identified through limited candidate-gene
approaches6–8,10,15,18,19,28. Only a small number of additional
GIS genes have been identified in systematic screens9,20,21,26.
Reasons for the limited success of these screens include: (1) the
use of assays that were not specific for GCRs; (2) the low GCR
rates detected in GCR assays are not well suited for large-scale
genetic screens; (3) the use of only a single GCR assay; and (4)
the lack of analysis of sufficient numbers of interacting mutations.
Here we used a two-stage screen design in which an in silico
approach was used to develop a highly enriched candidate gene
list sorted into candidate pathways29 followed by an extensive
genetic screen utilizing three different GCR assays and 43 query
mutations to identify genes and interacting pairs of genes that act
to suppress GCRs. Our results have provided a much more
detailed picture of the genetic network that acts to prevent GCRs
than previously available, and analysis of The Cancer Genome
Atlas (TCGA) data30–33 has suggested that the genes in this
network are potentially altered in a large proportion of ovarian
and colorectal cancers but not in acute myeloid leukaemia.
Results
Design of the systematic genome instability screen. Our strat-
egy for identifying new GIS genes was to generate mutant strains
using an adaptation of the Synthetic Genetic Array (SGA)
method34 and test them for increased genome instability. We
crossed a collection of candidate mutant strains (described below)
against strains containing one of three GCR assays (GCR query
strains; Fig. 1a) and against strains containing a GCR assay and
one of 43 mutations (GCRþmutation query strains). The 43
GCRþmutation query strains were included in the crosses
because some genes are cooperating Genome Instability
Suppressing (cGIS) genes in which mutations only affect
genome stability when combined with other mutations10. The
43 mutations affected known GIS genes and genes that clustered
with known GIS genes29 and were selected to maximize the
number of gene clusters surveyed (Fig. 1b,c).
The GCR assays select haploid cells resistant to both
canavanine (Can) and 5-fluoroorotic acid (5FOA) due to loss
of the CAN1 and URA3 genes on the left arm of chromosome V
(ref. 6). These GCRs have a breakpoint between the CAN1 and
URA3 genes and the most telomeric essential gene on the left
arm of chromosome V (PCM1); genomic features in this
breakpoint region influence the types of GCRs that are
formed7,8. The short repeated sequence GCR (sGCR) assay
contains single-copy sequences in the breakpoint region and
B100 bp of YCLWdelta5 sequence in the can1::PLEU2-NAT
locus that has homology to the long-terminal repeats from Ty1
and Ty2 retrotransposons (Fig. 1a). The segmental duplication
GCR (dGCR) assay contains the B4-kb DSF1-HXT13 segmental
duplication with divergent homology to regions of chromosomes
IV, X and XIV (ref. 8) in addition to the YCLWdelta5 fragment
(Fig. 1a). The Ty912-containing GCR (tyGCR) assay detects
GCRs mediated by homologous recombination (HR) with the
other Ty-related sequences in the genome (Fig. 1a)7. Single and
double-mutant haploid strains generated by the SGA procedure
were tested for increased accumulation of GCRs by determining
the number of CanR 5FOAR papillae observed after growing
patches from independent spore clones and replica plating the
patches onto GCR selection media (Fig. 1d,e). A numerical score
(0–5) was assigned to each patch by counting the total number of
papillae per patch, and a GCR strain score was calculated by
averaging the scores for all of the patches analysed for each
mutant (Fig. 1d). The GCR strain scores are not the direct
equivalent of GCR rates; doubling of the strain score corresponds
to an increase in GCR rate of an average of fivefold.
As determining GCR strain scores is labour intensive, we
implemented a two-stage genetic screening strategy to focus on a
subset of non-essential S. cerevisiae genes that were enriched in
GIS and cGIS genes. The first stage was our previous genome-
wide in silico screen that identified 1,041 candidate GIS genes29.
A preliminary investigation of B10% of these 1,041 genes
identified 34 new GIS genes and 1 new cGIS gene, revealing
that this group of genes was enriched for GIS genes but that
not all of the 1,041 genes were GIS genes29. In the second stage of
the screen, which is described in the present study, we eliminated
all essential genes from the candidate list of GIS genes and
added in all additional non-essential genes known to function
in the pathways identified by the 1,041 genes (see Methods;
Supplementary Data 1) resulting in 1,055 genes/mutations.
Finally, we added two additional mrc1 and rad53 alleles and a
leu2D control deletion for a total of 1,058 strains.
The first-generation set of 1,058 mutant strains was crossed to
the wild-type dGCR, sGCR and tyGCR query strains and
dGCRþ query mutation strains containing dia2D, exo1D, rrm3D
and rtt107D mutations, and the resulting progeny were evaluated
for increased GCR rates using patch tests (see Methods). On the
basis of these results, we generated a second-generation set of 639
mutant strains (see Methods and Supplementary Data 1). This
collection of mutants contained all of the mutations that either
increased the GCR rate in at least 1 GCR assay or interacted with
at least 1 of the dia2D, exo1D, rrm3D and rtt107D mutations in
the dGCR assay. The dia2D, exo1D, rrm3D and rtt107D
mutations were selected for evaluating candidate enhancing
mutations because together they interacted with the largest
number of bait mutations in a subset of the first-generation set
of mutant strains (see Methods). The 419 bait mutations
excluded were identified in the in silico screen on the basis of
causing increased sensitivity to DNA-damaging agents29, which
can reflect processes unrelated to DNA repair like small
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molecule export and detoxification. Consistent with this, the 419
excluded genes showed little if any genetic similarity to
bona fide GIS genes29 and were enriched for roles in the
endosome, Golgi complex, the ESCRT complex, the retromer
complex and general metabolism but not in DNA or
chromosome metabolism. Crossing of the second-generation
set of mutants to the remaining 39 dGCRþ query mutation
strains was then continued, and the resulting double-mutant
progeny were evaluated for increased GCR rates using patch tests
(see Methods).
Identification of GIS genes. Crossing the wild-type dGCR,
sGCR, and tyGCR query strains to the first-generation mutant
set generated 1,002, 995, and 1,009 single-mutant strains,
respectively (Supplementary Data 1). The GCR strain scores
for the leu2D control strains were 0.1, 0.94, and 2.67 for the
sGCR, dGCR, and tyGCR assays, respectively, and were con-
sistent with quantitative GCR rate measurements (Supplementary
Data 1). The distribution of strain scores for all of the mutations
tested in each GCR assay peaked around the strain scores for the
leu2D control strains, suggesting that most of the individual
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Figure 1 | Details of the systematic screen. (a). The sGCR, dGCR, and tyGCR assays involve simultaneous selection against the CAN1 and URA3 genes
inserted into the terminal non-essential region of the left arm of chromosome V. The GCR breakpoint region is the region between the telomeric CAN1 and
URA3 genes and the most telomeric essential gene, PCM1. Homologies within the GCR breakpoint regions, including theB100 bp fragment of YCLWdelta5
sequence introduced by can1::PLEU2-NAT, the DSF1/HXT13 segmental duplication, and the inserted Ty912 element, are indicated with grey boxes. (b). The
query mutations were primarily selected from the previously described gene clusters 3, 4, 32, 55, and 60 that were generated by clustering the candidate
GCR-suppression genes by genetic interactions29. Clusters 3, 4, and 32 had the greatest number of GCR-suppressing genes. Triangles indicate the relative
size of the cluster in terms of the number of genes, and the darker triangles are the clusters from which query mutations were selected. (c). Query
mutations (indicated by the boxes) in non-essential genes in cluster 4 were selected to provide the greatest genetic diversity by picking 1 or 2 mutations
from most sub-clusters. Query mutations were similarly selected from clusters 3 and 32. (d). The semi-quantitative scoring strategy assigns a number
between 0 and 5 to each patch depending on the number of papillae (0: no papillae; 1: 1–5 papillae; 2: 6–15 papillae; 3: 16- a countable number of papillae
(B150–200); 4: papillae that were too many or too close together to count; 5 (not shown): a lawn of papillae covering the entire patch). For each strain, a
minimum of 3 individual GCR patch scores were averaged to calculate the GCR strain score. Increases in the GCR strain score were paralleled by increases
in GCR rates measured by the fluctuation method. (e). Patch tests documenting genetic interactions involving mutations in either CKB2 or EXO1. The status
of CKB2 or EXO1 is indicated across the top of each set of patches, and the bait mutations tested are indicated to the left of each set of patches.
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mutations tested did not strongly affect genome instability
(Fig. 2a–c).
To determine a cutoff score for identifying mutations causing
increased GCR rates, we determined GCR rates for 101 single-
mutant dGCR strains and all 43 leu2D queryD double-mutant
dGCR strains from crosses with the dGCRþ query mutation
strains (Supplementary Tables 1 and 2). We found a robust
correlation between the GCR strain scores and GCR rates (Fig. 2d),
despite a small but consistent increase in dGCR rates that was
observed in strains from the systematic crosses, which was
potentially due to GCRs mediated by the YCLWdelta5 fragment
at the can1::PLEU2-NAT locus (Supplementary Tables 2 and 3;
Supplementary Fig. 1). Using the GCR strain scores and rates for
the 144 systematically generated dGCR assay-containing strains, we
determined that a cutoff score of 1.4 (0.4 above the wild-type score)
balanced the false-positive and false-negative errors in identifying
mutations in GIS genes (Supplementary Fig. 2; Methods).
We generated a comprehensive list of GIS genes by combining
the GIS genes identified here with those previously known.
Initially, we selected all single mutations that caused GCR strain
scores that were 0.4 or more above the wild-type score in any
GCR assay (Supplementary Data 1; Supplementary Fig. 3). We
then removed mutations that caused less than a threefold increase
in GCR rate and included mutations that caused at least a
threefold increase in rate, regardless of GCR strain scores
(Supplementary Tables 2, 4 and 5; Supplementary Fig. 4). Finally,
we included mutations previously shown to increase the GCR rate
by threefold or more, including mutations in essential genes not
studied here and mutations in genes identified in studies using
GCR assays lacking repetitive sequences in the GCR breakpoint
region (single-copy or unique sequence GCR assays; designated
here as uGCR assays6,8 and previously summarized29;
Supplementary Data 1). We observed 75 genes that suppressed
GCRs in the dGCR assay, 71 genes in the tyGCR assay, 80 genes
in the sGCR assay and 105 genes in the uGCR assays. The higher
number of GCR suppressing genes identified in the uGCR assays
is primarily the result of candidate gene studies that included
alleles of essential genes not tested here and mutations that cause
small but significant increases in quantitative GCR assays, which
were too small to reliably detect by the semi-quantitative scoring
method used here. Altogether, we identified 182 S. cerevisiae GIS
genes, 50 of which suppress genome instability in at least 3 of the
4 GCR assays (Fig. 3; Supplementary Data 1).
This analysis identified 64 previously unrecognized GIS genes,
reidentified 62 known GIS genes including 20 identified in
our previous test validation29, and failed to reidentify 56
previously recognized GIS genes. Of the 56 genes that were not
reidentified in this screen, 13 were not discoverable, as these
genes were either essential for viability or mating, and 43
caused only a small increase in GCR rate that could not be
easily identifiable by patch scores. Fourteen of these 43 genes
were found in our previous test validation29. Forty two of these
43 were subsequently found as interactors in our cGIS screen
(see below), which would be expected to identify weak alleles
as interacting mutations. In total, this study and our previous
test validation of the list of candidate GIS genes29 identified
98 new GIS genes that were not known when we constructed
the candidate list29. Examples of previously unrecognized
GIS genes included VID22 and YDJ1. VID22 encodes a
partner of Tbf1 involved in transcriptional regulation35,36 and
DSB repair37. YDJ1 encodes the major cytosolic Hsp40/DnaJ
co-chaperone that acts in protein maturation and stabilization38.
The imperfect overlap of mutations causing increased GCR
strain scores in the different assays suggests that some
mutations have different effects on GCRs in different genomic
contexts8, which was verified by GCR rate measurements
(Supplementary Table 1).
To determine the efficiency of our preselection of candidate
GIS genes29, we crossed the dGCR assay strain to five
randomly selected 96-well plates of mutant strains from the
S. cerevisiae deletion collection and determined GCR strain scores
for the progeny (Supplementary Data 1). Only 1 of the 463
single mutants scored, ydl118wD, which was not previously
identified, caused an increased GCR strain score. This deletion
was tested in the initial cross but did not cause an increased
GCR strain score, likely because it only causes a small increase in
GCR rate. Extrapolating to the entire deletion collection,
we estimate that our method potentially missed approximately
eight GIS genes and that we identified 96% of the GIS genes.
However, ydl118wD was identified in the cGIS gene screen
described below; this suggests that at least some of the
approximately eight GIS genes that were predicted to not be
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Figure 2 | Assaying single-mutant strains using GCR strain scores. (a–c). Histograms of the distribution of GCR strain scores for single-mutant strains
from the sGCR (a), dGCR (b) and tyGCR (c) assays reveal that the average GCR strain score increases with the GCR rate for each GCR assay and that the
score of the leu2D control strain (grey triangle) generally lies at the peak of each histogram, suggesting that many of the mutations tested do not
substantially affect the GCR strain score as single mutations. (d). The fold increase in the GCR rate is correlated with the GCR strain score for
systematically generated strains containing the dGCR assay.
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identified in the single-mutant screen were likely identified in the
cGIS gene screen.
Identification of cGIS genes. We recovered and tested 25,974
double mutants from the crosses of the 43 dGCRþ query
mutation strains with the first-generation (dia2D, exo1D, rrm3D
and rtt107D) and second-generation (the remaining 39
dGCRþ query mutation strains) bait strain sets (Methods;
Supplementary Data 1). As the 43 query mutations were also
present as bait mutations, we obtained 801 pairs of double-
mutant strains (out of a possible 903) generated as both
query bait or bait query combinations. The individual pairs
of these double mutants had consistent GCR strain scores
(Supplementary Fig. 5). The scores of the double-mutant strains
were distributed about the score of the query mutants as for the
single-mutant strains, including mutations causing reduced
scores (for example, rsc30D), scores essentially identical to
wild-type (for example, lge1D) or increased scores (for example,
ckb2D and rad17D) (Fig. 4a–h; Supplementary Figs 6–11).
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Figure 3 | Summary of the increased GCR rates of single-mutant strains identified using patch tests. (a). Venn diagram indicating the number of genes
that suppress GCRs in each of the GCR assays used. (b). Genes implicated in suppressing GCRs in more than one GCR assay. The boxes indicate the assays
(d¼ dGCR, s¼ sGCR, ty¼ tyGCR, u¼ uGCR) in which the listed gene suppresses (grey) or does not suppress (white) GCRs. Note that uGCR assays are
GCR assays lacking repetitive sequences in the GCR breakpoint region that have been utilized in previous studies6,8. Many genes unique to the uGCR assay
are primarily genes in which mutations cause small but significant increases in GCR rates, which were identified using fluctuation assays but are difficult to
identify by the semi-quantitative patch score method used here. (c). Genes implicated in suppressing GCRs in only one GCR assay, annotated as in b.
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Double-mutant strains (n¼ 3,149 (B13%)) that had GCR
strain scores that were at least 0.4 (the single-mutant strain
differential score) greater than the higher of the two single-
mutant strain scores were suggestive of a genetic interaction
causing a greater than additive increase in GCR rate
(Supplementary Data 1). GCR rate determination of 66 selected
double mutants predicted to show a genetic interaction revealed
that 71% of these double-mutation combinations resulted in a
synergistic increase in GCR rate compared with that of the
respective single mutants. Thus, increased double-mutant GCR
strain scores were a good indicator for synergistic interactions
(Supplementary Table 6). Raising the strain score differential
above 0.4 did not substantially improve the identification of
synergistic interactions; this suggests that the selection of false-
positive double mutants reflects some biological property of the
double mutants (for example, selection of suppressor mutations)
affecting the patch scores or rates rather than an inappropriate
cutoff score. Despite this, double-mutant GCR strain scores
reidentified many previously known genetic interactions10,19,
such as the redundancy between the REV1–REV3–REV7- and
MMS2–UBC13-dependent branches of post-replication repair,
the dependence on SRS2 of the increases in GCR rates caused by
rad18D and rad5D single mutations, and the redundancy of
MEC1- and TEL1-mediated suppression of the formation of
GCRs as well as many new interacting mutations (Supplementary
Fig. 12).
The query mutations interacting with the largest number of
mutations were ckb2D, exo1D, rad17D, yta7D, mec1D, mms4D
and rrm3D (Fig. 4i), and the bait mutations interacting with the
largest number of query mutations were est1D, ckb2D, mrn1D,
exo1D, chk1D, isu1D, rnh201D, ckb1D and tof1D (Fig. 4j). Two
mutations illustrating the complexity of these interactions were
ckb2D and exo1D, which both interacted with checkpoint defects
and also interacted with each other (Supplementary Data 1;
Supplementary Table 7), indicating that casein kinase II and Exo1
function in different GCR suppressing pathways, both of which
interact with checkpoint pathways. Mutations causing very high
(43) GCR strain scores as single mutations tended to have few
interactions, possibility due to difficulties in scoring strains that
come close to saturating the assay. In total, 595 mutations
interacted with at least one query mutation; 438 of the affected
genes were distinct from the 182 GIS genes and hence were
cGIS genes (Supplementary Data 1). In total, mutations in 620
genes (182 GIS genes and 438 cGIS genes; 13% of the 4,848
non-essential S. cerevisiae ORFs) were identified as causing or
enhancing genome instability.
To identify the most robust interactions, we searched for
interactions between a query mutation and mutations in multiple
genes encoding components of an annotated complex or
pathway, which we termed ‘modules’ (Fig. 4k; Methods). We
found shared interaction for 77 modules (Table 1). Mutations
affecting an additional 91 modules had interactions that were not
shared (Supplementary Data 2); although this included 64
complexes where only a single gene was tested. Mutations
affecting only two modules, Mre11-Rad50-Xrs2 and Sgs1-Top3-
Rmi1, caused significant increases in GCR rates but lacked
interactions with other mutations; the lack of interacting
mutations in these cases was likely due to the fact that single
mutations in the genes encoding these complexes cause high GCR
strain scores that saturate the assay (B4.0).
Inactivation of GIS genes in human cancers. To determine
whether defects in GIS genes might occur in cancer, the ovarian
cancer, colorectal cancer and acute myeloid leukaemia (AML)
TCGA data were analysed30–32. The genes analysed were the
human homologues of the 182 S. cerevisiae GIS genes plus 13
additional genes that act in pathways and protein complexes
defined by the GIS genes (hGIS1, 214 genes; Supplementary Data
3) and an expanded list (hGIS2, 279 genes; Supplementary Data
3) that included human DNA repair genes that function in
pathways identified in S. cerevisiae but lack an S. cerevisiae
homolog (for example, BRCA1 and BRCA2) or have an S.
cerevisiae homolog that was not initially identified because of a
borderline score (for example, NHEJ1 and H2AFX).
To identify potential cancer genes, we used a scoring system
(S-score)39 that integrates genome-wide data (copy-number
variation, expression, methylation and mutations) from a set of
tumour samples. In the first analysis, human GIS genes
were analysed for signatures consistent with tumour
suppressors (S-scoresr 2) or proto-oncogenes (S-scoresZ2;
Supplementary Data 3). Genes from hGIS1 and hGIS2 with
S-scoresr 2 were enriched in ovarian cancer cases (hGIS1, 26
genes, P¼ 0.0008; hGIS2, 41 genes, Po0.0001). In contrast, there
was no enrichment in human GIS genes with S-scoresZ2 in the
ovarian cancer cases (hGIS1, 43 genes, P¼ 0.31; hGIS2, 54 genes,
P¼ 0.40), and these genes were not studied further. The 41 genes
from hGIS2 with S-scoresr 2 and 4 additional genes with
S-scores between  2 and  1.95 in ovarian cancer were analysed
for reduced copy number (GISTIC scores of  1 or  2)
associated with reduced expression (Z-scoreso 2). Reduced
copy number associated with reduced expression of 1 to 19 of
these 45 genes was observed in 97% of 527 ovarian cancer cases
(Supplementary Table 8; Supplementary Data 4). A box plot of
the data for one such gene, RAD17, and the frequency of
occurrence for the top 20 such genes in ovarian cancer are shown
in Fig. 5a,b. There were also three genes that appeared to be
silenced in 12% of 537 ovarian cancer cases (Supplementary
Table 8; Supplementary Data 4). Genes with S-scoresr 2 were
enriched (hGIS1, 18 genes, P¼ 0.0001; hGIS2, 18 genes.
P¼ 0.0015) in colorectal cancer cases; in contrast, human GIS
genes with S-scoresZ2 were not enriched (hGIS1, 12 genes,
P¼ 0.10; hGIS2, 16 genes, P¼ 0.058) and were not studied
further. The 18 genes with S-scores r 2 and 2 genes with
S-scores between  2 and  1.95 in colorectal cancer cases were
further analysed. Reduced copy number associated with reduced
expression of 1 to 8 of these 20 genes was observed in 54% of 456
colorectal cancer cases, and 4 genes had apparent silencing in
10% of 463 colorectal cancer cases (Supplementary Table 8;
Supplementary Data 5). In the case of AML (222 samples), there
was no enrichment of human GIS genes with S-scoresr 2 in
hGIS1 (P¼ 0.067) and a marginal enrichment of human GIS
genes with S-scoresr 2 in hGIS2 (P¼ 0.045). There was no
enrichment for human GIS genes with S-scoresZ2 in both hGIS1
(P¼ 0.085) and hGIS2 (P¼ 0.194) and no genes with apparent
silencing were identified.
In the second analysis, the number of potential loss-of-function
(LOF) mutations (nonsense mutations, frameshift insertion/
deletions, in-frame insertion/deletions and splice-site mutations)
in the hGIS1 and hGIS2 genes was tabulated for 476 ovarian
cancer cases and 537 colorectal cancer cases. For ovarian cancer,
LOF mutations were not enriched in hGIS1 genes (P¼ 0.87) but
were enriched in hGIS2 genes (Po0.0001); this increase in
significance was due to the presence BRCA1 and BRCA2 in the
hGIS2 gene list, which accounted for 70% of the LOF mutations
in hGIS2 genes. Analysis of the enrichment of classes of the LOF
mutations for the hGIS2 genes in ovarian cancer revealed that
deletions (includes frameshift deletions; Po0.0001), insertions
(includes frameshift insertions; Po0.0001), frameshift deletions
(Po0.0001), frameshift insertions (Po0.0001) and nonsense
mutations (P¼ 0.0015) were present at significantly increased
levels; many but not all of these LOF mutations were in BRCA1 or
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Figure 4 | Identification of genetic interactions involved in suppressing genome instability. (a,c,e,g). Plots of the cumulative fraction of mutations below
specific GCR strain scores for strains containing bait mutations and in addition one of the rsc30D, lge1D, ckb2D or rad17D query mutations (solid line)
compared with the distribution from the crosses of the bait mutations to the wild-type strain (dashed line). (b,d,f,h). Histograms of the number of
mutations in combination with rsc30D, lge1D, ckb2D or rad17D as a function of the GCR strain score difference, which is the GCR strain score of the double-
mutant strain (aD bD) minus the GCR strain score of the higher of the two single-mutant strains (aD or bD). (i). Plot of the number of GCR-based
interactions as a function of the single-mutant GCR strain score for the 43 mutant query strains. Query mutations with large numbers of interactions or
those displayed in a–h are indicated. (j). Plot of the number of GCR-based interactions as a function of the single-mutant GCR strain score for bait
mutations. Bait mutations with large numbers of interactions are indicated. (k). Analysis of physical interaction data for the casein kinase II complex is
shown (left) with reported physical interactions in BioGrid (lines) between complex components (circles). Components with known GCR interactions are in
red; untested components (CKA2) or those tested with only four query mutations (CKA1) are in grey. Display of the genetic interactions between the ckb1D
and ckb2D bait mutations and the 43 query mutations (right). Bar heights indicate the strain score for the double mutant, and bar colours correspond to the
presence (red) or absence (blue) of an increased level of genome instability in the double mutant as observed in patch tests relative to the respective single
mutant with the highest level of increased genome instability; the horizontal dashed line corresponds to the GCR strain score of the higher of the two single
mutations. Missing bars and query names in grey correspond to double-mutant strains that were not generated in the crosses performed.
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Table 1 | Modules with shared interactions in the dGCR enhancer screen.
Process Module*
DNA repair Core mitotic homologous recombination Mms2–Ubc13 complex
Base-excision repair Mms4–Mus81 complex
Cul8–RING ubiquitin ligase complex Msh2–Msh6 complex
DNA ligase IV complex Nucleotide-excision repair factor 1 (NEF1) complex
DNA polymerase zeta—Rev1 complex Nucleotide-excision repair factor 4 complex
Ku complex Rad1–Rad10–Saw1 complex
Mlh1–Mlh2 complex Ribonuclease H2 complex
Mlh1–Mlh3 complex Shu complex
Mlh1–Pms1 complex Slx1–Slx4 complex
DNA replication DNA polymerase epsilon complex
Ribonucleoside-diphosphate reductase complex
Telomerase
Chromosome cohesion and Ctf18 RFC-like complex
segregation Ctf19 complex (includes COMA complex)
Dynactin complex
Monopolin
Msh4–Msh5 complex
Prefoldin complex
Cell cycle checkpoints Anaphase-promoting complex (APC/C)
Cdc28 cyclin-dependent kinase complexes
Mec1–Ddc2 complex
Protein phosphatase (PP4) complex
Rad17–Ddc1–Mec3 complexþRad24-Rfc2–5 clamploader
Spindle checkpoint
Tof1–Csm3 complex
Chromatin/transcription/ Carboxy-terminal domain protein kinase complex
mRNA processing CCR4-NOT core complex
Cdc73/Paf1 complex
Chromatin assembly complex
Chz1–Htz1–Htb1 complex
COMPASS complex
Cytoplasmic mRNA processing body
Cytoplasmic Sm-like complex
Elongin–Cullin–Socs (ECS) ligase complex
HIR complex
Ino80 complex
ISW1a chromatin remodelling complex
Mediator complex
NuA3 histone acetyltransferase complex
NuA4 histone acetyltransferase complex
Rpd3L complex
Rpd3S complex
RNA polymerase I complex
RSC complex
SAGA complex
Set3C complex
SLIK (SAGA-like) complex
Spt3–Spt8 SAGA subunit of SAGA complex
Swr1 complex
U6 snRNP
Nuclear pore Nuclear pore nuclear basket
Nuclear pore outer ring
Proteasome/protein Doa10 ubiquitin ligase complex
degradation Hrd1p ubiquitin ligase ERAD-L complex
proteasome 19/22S regulator
proteasome 20S complexþUmp1 chaperone,
Rad6–Ubr1 complex
Ula–Uba3 complex
Other AP-3 adaptor complex
Casein kinase II complex
Chs5p/Arf-1 binding proteins (ChAPs)
ESCRT III complex
Golgi transport complex
HMC complex
Kel1–Kel2 complex
NatA complex
Sod1–Ccs1 complex
Ssk1–Ssk2 complex
dGCR, duplication-mediated gross chromosomal rearrangement assay; mRNA, messenger RNA
*See Supplementary Data 2 for genes in each module.
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BRCA2 (Supplementary Data 3). Overall, 27% of the 476 ovarian
cancer samples had LOF mutations in at least 1 of 44 predicted
human GIS genes, with 1–3 genes mutated per sample
(Supplementary Table 8; Supplementary Data 6). LOF mutations
in both sets of GIS genes were enriched in the colorectal
cancer TCGA cases (hGIS1, Po0.0001; hGIS2, P¼ 0.0012). The
frequency of LOF and predicted deleterious missense mutations
for the top 20 hGIS2 genes in colorectal cancer is shown in
Fig. 5c. Deletions (including frameshift deletions; hGIS1,
P¼ 0.0004; hGIS2, P¼ 0.0038), mononucleotide repeat
frameshifts (hGIS1, Po0.0001; hGIS2, Po0.0001) and
splice-site mutations (hGIS1, P¼ 0.0003; hGIS2, P¼ 0.0002)
were present at significantly increased levels in both hGIS1 and
hGIS2 genes, and nonsense mutations were present at statistically
significant increased levels in hGIS1 and at borderline significant
levels in hGIS2 (hGIS1, P¼ 0.01; hGIS2, P¼ 0.0613)
(Supplementary Data 3). A proportion of colorectal cancer has
mismatch repair (MMR) defects associated with high rates of
accumulating mutations32. We therefore repeated the analysis
using a sample set in which the MMR-defective cases had been
excluded and found that deletions (including frameshift deletions;
hGIS1, P¼ 0.001; hGIS2, Po0.0001), nonsense mutations
(hGIS1, P¼ 0.001; hGIS2, P¼ 0.0046), frameshift deletions
(hGIS1, P¼ 0.032; hGIS2, P¼ 0.029), mononucleotide repeat
frameshifts (hGIS1, P¼ 0.0016; hGIS2, P¼ 0.0042) and splice-site
mutations (hGIS1, P¼ 0.0004; hGIS2, Po0.0001) were present at
significantly increased levels in both hGIS1 and hGIS2, and
frameshift insertions were present at significantly increased levels
in only hGIS2 (P¼ 0.022). This indicates that the accumulation of
these classes of mutations in the colorectal cancer cases was not
due to MMR defects. Overall, 30% of the 537 colorectal cancer
samples had LOF mutations in at least 1 of 185 predicted human
GIS genes, with 1–36 genes mutated per sample (Supplementary
Table 8; Supplementary Data 7). In the case of AML, there was no
enrichment of LOF mutations in the GIS genes (hGIS1, P¼ 1.00;
hGIS2, P¼ 0.99), and as a result, individual classes of mutations
were not analysed.
All of the gene inactivation data were merged, and the
proportion of different classes of gene inactivation was
determined (Fig. 5d; Supplementary Data 8). LOF mutations
and LOF mutations plus those missense mutations that scored as
‘predicted deleterious’ in at least 5 of 6 function prediction
tests were considered separately. In ovarian cancer, the gene
inactivation signature was dominated by cases with reduced copy
number associated with reduced expression. Colorectal cancer
showed a different pattern with less overlap between the cases
with mutations and the cases with reduced copy number
associated with reduced expression. Overall, when only LOF
mutations were considered, a minimum of 93% of ovarian cancer
cases and 66% of colorectal cancer cases had a signature of
inactivation of one or more predicted GIS genes (Fig. 5d),
although these figures are an underestimate because not all
samples were analysed for all types of alterations. It should be
noted that the colorectal cancer cases did include cases with
alterations in MMR genes (MSH2, MSH6, MSH1 and PMS2),
including 46 cases with only LOF mutations and 50 cases with
LOFþ predicted deleterious missense mutations (19 of these
cases had silencing of MLH1, 1 of which also had LOH of
MLH1), all but 3 of which had alterations in other GIS genes. In
the ovarian cancer cases, there were 23 cases of reduced copy
number and reduced expression of MLH1, 3 cases with a LOF
mutation in an MMR gene and 2 cases with a predicted
deleterious missense mutation in an MMR gene; all of these cases
had alterations affecting other GIS genes. This indicates that
potential MMR defects account for only a small fraction of the
alterations affecting GIS genes; it should be noted that MMR
defects cause increased GCR rates in addition to increased
mutation rates8.
The 103 human homologues of the 98 newly identified
S. cerevisiae GIS genes were analysed separately (Supplementary
Data 9). When only LOF mutations, reduced copy number with
reduced expression and silencing were considered 64% of
ovarian cancer cases had defects affecting at least 1 of 24 of
the 103 human genes, and 47% of colorectal cancer cases had
defects affecting at least 1 of 67 of the 103 genes. When predicted
highly deleterious missense mutations were included, 65% of
ovarian cancer cases had defects affecting at least 1 of 37 of the
103 genes, and 51% of colorectal cancer cases had defects
affecting at least 1 of 84 of the 103 genes. This indicates that the
newly identified GIS genes likely account for a large number of
human GIS genes in which defects can cause increased genome
instability in human cancers.
Discussion
Here we developed methods to screen the S. cerevisiae systematic
deletion collection to identify new GIS genes, identify genes that
interact to suppress the formation of GCRs and identify candidate
human genes for the analysis of cancer genomics data to identify
potential GIS gene defects in human cancers. This analysis
increased the total number of known GIS genes to 182, including
98 new GIS genes identified here and during our targeted
validation of the starting 1,041 candidate genes. We also
identified 438 cGIS genes and an extensive catalogue of genetic
interactions affecting genome stability. Analysis of ovarian and
colorectal cancer TCGA data31,32 showed that the majority of the
cancer cases analysed (a minimum of 93% of ovarian and 66% of
colorectal cancer cases) appeared to have defects affecting one
or more genes that were homologues of the S. cerevisiae GIS genes
or act in the pathways identified by the GIS genes. In contrast,
AML, a cancer with little genome instability33, did not appear to
have defects affecting GIS genes. Thus, genetic or epigenetic
changes causing increased genome instability are likely common
in some types of cancer, but due to the large number of GIS
genes, the defect signature for any single gene can be weak.
Almost half of the 182 S. cerevisiae GIS genes suppress the
formation of GCRs detected in multiple GCR assays. The
common pathways identified typically include genes involved in
DNA metabolism, including DNA replication and repair, and
genes involved in checkpoint signalling in response to
DNA damage and replication errors. Some of the genes identified,
such as RAD27 and TSA1, likely function by suppressing the
formation of DNA damage27,40. Other genes, such as those
encoding the Mre11-Rad50-Xrs2 and Sgs1-Top3-Rmi1
complexes, likely process DNA damage generated by other
mechanisms41, such as DNA replication errors. A number of
genes have less clear roles in suppressing genome instability, such
as VID22, YDJ1, SSZ1 and CKB2. The fact that many GIS genes
suppress GCRs detected in multiple assays that probe different
genomic contexts indicates that these genes can suppress the
formation of many types of GCRs7,8,10,12,15. A notable exception
are pif1 mutations that cause a defect in suppression of de novo
telomere additions, which appears insensitive to genomic
context8,18,42. In contrast, a number of genes suppress GCRs
detected by subsets of GCR assays (Fig. 3). In most cases, the
mechanisms underlying this specificity are not yet understood;
however, in the case of MSH2 and MSH6, the heteroduplexes
formed by non-allelic homologous recombination (HR) during
the formation of duplication-mediated GCRs are likely to contain
a higher density of mispairs and hence be better recognized by
MMR and subjected to heteroduplex rejection7,8 than
heteroduplexes formed in the tyGCR and sGCR assays.
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Mutations that enhance the accumulation of GCRs can in
principle act in compensatory or parallel pathways or can have
more complicated relationships involving genes within path-
ways43. In addition, mutations can result in increased levels of
DNA damage that can lead to GCRs when repair mechanisms are
defective or are saturated by the increased levels of DNA damage.
Many mutations showing genetic interactions, such as exo1D,
cause increased GCR rates as single mutations. Mutations
like these could affect the response to normal levels of
spontaneous DNA damage as well as DNA damage that is
either induced in the absence of other pathways or is normally
repaired in part by other pathways. In contrast, a number of
enhancer mutations, such as tel1D cause no increase in GCR rates
as single mutations10. These mutations may either result in
increased DNA damage that is efficiently repaired so long as the
relevant repair mechanisms are functional and not overwhelmed
by other sources of damage or inactivate a redundant pathway.
Defects in the genes encoding complexes can show the same types
of interactions, regardless of whether defects in all of the
genes encoding a complex behave similarly (such as RNH201,
RNH202 and RNH203 as well as MMS2 and UBC13) or whether
defects in only a subset of the genes encoding a complex have
similar properties (for example, SPT3, SPT8 encoding part of
SAGA).
The systematic identification of S. cerevisiae GIS genes has
facilitated a pathway-based analysis of human cancer genomics
data. We have focused on ovarian and colorectal cancer, two
cancers with genome instability that appear to have different
relative frequencies of copy-number changes and mutation driver
alterations30, as well as AML, a cancer that is associated with little
if any genome instability30. In the case of the ovarian cancer
TCGA data, 23% of the samples with any data had LOF
mutations in GIS gene homologues, with 65% of the samples with
LOF mutations having LOF mutations in BRCA1 and BRCA2 as
previously reported31; no other individual GIS gene homolog had
a LOF mutation in 40.5 to 1% of the samples. In contrast, there
was a high frequency of copy-number alterations, including both
copy-number reductions and homozygous deletions, associated
with reduced expression of GIS gene homologues in ovarian
cancer. This included 17% of the samples that had homozygous
deletions of 1 to 9 GIS gene homologues per sample,
approximating the frequency of samples with BRCA1 or BRCA2
LOF mutations. In contrast, the colorectal cancer TCGA data
showed a higher proportion of samples and GIS gene homologues
with LOF mutations and a lower yet high proportion of samples
and GIS gene homologues with copy-number alterations associated
with reduced expression. A minimum of 93% of ovarian cancer
TCGA cases and 66% of colorectal cancer TCGA cases had
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Figure 5 | Analysis of the ovarian and colorectal cancer TCGA data for alterations in GIS genes. This figure summarizes the data analysis presented in
Supplementary Table 8 and Supplementary Data 4–8. (a). Box plot of the RNA Seq data for the copy number (GISTIC  2, Homozygous Deletion; GISTIC
 1, Heterozygous Loss; GISTIC 0, Diploid; GISTIC 1, Gain) versus the Z-score for mRNA expression of RAD17 in ovarian cancer. (b). Histogram of the
frequency of reduced copy number with reduced mRNA expression for the top 20 most-altered GIS genes in ovarian cancer. (c). Histogram of the
frequency of mutations in the top 20 most-altered GIS genes in colorectal cancer. Data forMSH2,MSH6 andMLH1 were excluded as defects in these genes
predominantly cause increased rates of accumulation of point mutations. Predicted deleterious missense mutations are those that scored as deleterious in
5 or 6 out of 6 functional prediction tests. (d). Pie charts showing the % of ovarian (left) and colorectal (right) cancer samples with different combinations
of mutations, reduced copy number with reduced expression and silencing among all samples for which any type of genomics data were available. Analysis
of LOF mutations alone (Top) and LOFþpredicted deleterious missense mutations (Bottom) are presented separately. Note that 19% of the ovarian and
25% of the colorectal cancer cases were not analysed for all types of potential alterations, and consequently the values presented are an underestimate.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms11256
10 NATURE COMMUNICATIONS | 7:11256 | DOI: 10.1038/ncomms11256 | www.nature.com/naturecommunications
alterations (not considering predicted deleterious missense
mutations) affecting one or more GIS gene homologues, with
only 5 and 8% of the samples, respectively, having alterations in
genes expected to cause a strong MMR defect (MSH2, MSH6,
MLH1 and PMS2) and hence a mutator phenotype. Overall, these
results suggest that a high prevalence of alterations in GIS genes
can explain how genome stability is compromised in these two
cancers. Consistent with this view, there was no evidence for
significant alteration of GIS genes in AML, a cancer that is not
associated with high levels of genome instability30. Defects in some
of the human genes identified here have been implicated in cancer
(for example, BRCA1, BRCA2, ATM, BLM, REV3L and PBRM1),
and some of the genes have been associated with the suppression of
genome instability (for example, WRN, BLM, ATM, ATR, BRCA1
and BRCA2) or with pathways thought to act in the suppression of
genome instability (for example, RAD17, RAD50, XRCC6 and
TP53BP1)44,45. Our functional studies in S. cerevisiae provide
evidence that many of the human GIS gene homologues likely act
in the suppression of genome instability in human cells and
provide a restricted, prioritized list of human genes for genetics and
functional validation studies.
Methods
Plasmid construction. The plasmid pRDK1590, which is a version of pRS315
(ref. 46) in which the LEU2 open reading frame was replaced by the
nourseothricin-resistance (NAT) open reading frame, was constructed by gap
repair in the S. cerevisiae strain BY4741 as follows. BY4741 was transformed with
AflII-digested pRS315, and the NAT open reading frame amplified from plasmid
pFA6a-natNT2 using the primers 50-CTTTTACATTTCAGCAATATAT
ATATATATTTCAAGGATATACCATTCTAatgggtaccactcttgacga-30 and 50-ATTT
CATTTATAAAGTTTATGTACAAATATCATAAAAAAAGAGAATCTTTttag
gggcagggcatgctca-30 , where uppercase letters correspond to pRS315 sequence and
the lowercase letters correspond to NAT sequence. The plasmid pRDK1593 was
generated by sub-cloning a PLEU2-NAT-containing BsrGI to XbaI fragment from
pRDK1590 into pRS305 (ref. 46) digested with BsrGI and XbaI and was
subsequently used as a template for PCR amplification of PLEU2-NAT for
generating gene disruptions.
Query strain construction. The selectable markers used in the MATa query
strains in systematic mating in the original SGA protocol34 are incompatible with
the genetic markers required for GCR assays. Therefore, different selectable
markers were introduced into MATa query strains containing GCR assays. The
selected markers were as follows. First, because the GCR assay requires CAN1,
which interferes with use of canavanine in combination with thialysine to kill
diploid strains in the SGA protocol34, we introduced a deletion of LYP1 and the
cycloheximide-resistant cyh2-Q38K mutation47 into our strains, allowing the use of
thialysine and cycloheximide to kill diploid strains in our SGA protocol. Second,
we introduced a copy of LEU2 driven by the MFA1 promoter near the YFR016C
gene to select for MATa haploid progeny. Third, we replaced the native CAN1 gene
with a selectable nourseothricin-resistance gene driven by the LEU2 promoter in
the dGCR and sGCR assay strains. The MATa and MATa strains with PLEU2-NAT
were nourseothricin-resistant when grown on complete synthetic media (CSM;
made with dropout mixes from US Biological). However, the MATa strains were
not nourseothricin-resistant on YPD (1% Bacto-yeast extract, 2% Bacto-peptone,
2% dextrose) medium, which is potentially due to increased expression of the Leu2
protein in MATa strains, resulting in downregulation of the LEU2 promoter; this
did not interfere with the selection scheme because the selections were performed
in the appropriate CSM-dropout media.
The required strains were constructed in the following steps. First, BY404
(MATa ade2::hisG his3D200 leu2D0 trp1D63 ura3D0) was crossed with RDKY3686
(MATa hom3–10 lys2-10A his3D200 leu2D1 trp1D63 ura3–52) and sporulated to
isolate RDKY7595 (MATa lys2-10A hom3–10 his3D200 leu2D0 trp1D63 ura3D0)
and RDKY7594, a MATa version of RDKY7595. URA3 was amplified from pRS306
with the primers 50-GGAGTTTATGTTTATATACACCGGT GTAGGCTGTGC
GTTGGTGTGAACACgagca gattgtactgagagtgcacc-30 and 50-GGCTGTATGACTA
CAGTTGCATGCG GAGACGGCTTCAACAGCAACAGCAActccttacgcat ctgtgc
ggtatttc-30 and inserted 3’ to the YFR016C gene to generate RDKY7596. The
iYFR016C::URA3 insertion was then replaced with a PMFA1-LEU2 construct
amplified from FYAT258, generously provided by D. Bernard48, using the primers
50-GGA GTT TAT GTT TAT ATA CAC CGG TGT AGG CTG TGC GTT GGT
GTG AAC ACg taa caa tag atc cac tag-30 and 50-GGC TGT ATG ACT ACA GTT
GCA TGC GGA GGC TTC AAC AGC AAC AGC Aaa ttt aag tat tca ctt tcg-30 to
generate RDKY7597 (MATa lys2-10A hom3–10 his3D200 leu2D0 trp1D63 ura3D0
iYFR016C::PMFA1-LEU2). RDKY7594 was crossed to RDKY7597 and sporulated to
generate RDKY7598, a MATa version of RDKY7597. HXT13 was replaced by
URA3 in RDKY7598 to generate RDKY7599. A wild-type copy of LYS2 was
amplified from BY4741 and used to replace the lys2-10A allele in RDKY7599 to
generate RDKY6970. The LYP1 gene in RDKY6970 was then replaced by TRP1 to
generate RDKY6971. A cyh2mutation, determined to be cyh2-Q38K by sequencing,
was selected in RDKY6971 on YPD plates containing 10 mgml 1 cycloheximide
(Sigma) to generate RDKY6975 (MATa hom3–10 his3D200 leu2D0 trp1D63
ura3D0 lyp1::TRP1 iYFR016C::PMFA1-LEU2 cyh2-Q38K hxt13::URA3). RDKY6975
and RDKY7597 were crossed, and the resulting diploid was sporulated to
obtain RDKY7625 (MATa hom3–10 his3D200 leu2D0 trp1D63 ura3D0 lyp1::TRP1
iYFR016C::PMFA1-LEU2 cyh2-Q38K). The PLEU2-NAT gene was amplified from
pRDK1593 and integrated into the CAN1 locus in RDKY7625 to generate
RDKY7629. The CAN1/URA3 cassette with flanking targeting sequences was
amplified from pRDK1378 and pRDKY1379 and integrated into RDKY7629 to
generate the dGCR query strain RDKY7635 (MATa hom3–10 ura3D0 leu2D0
trp1D63 his3D200 lyp1::TRP1 cyh2-Q38K iYFR016C::PMFA1-LEU2 can1::PLEU2-NAT
yel072w::CAN1/URA3) and the sGCR query strain RDKY7964 (MATa hom3–10
ura3D0 leu2D0 trp1D63 his3D200 lyp1::TRP1 cyh2-Q38K iYFR016C::PMFA1-LEU2
can1::PLEU2-NAT yel068c::CAN1/URA3), respectively (Supplementary Table 9).
The tyGCR assay strain was constructed by crossing RDKY6975 with RDKY6593
(ref. 7) and sporulating the resulting diploid to recover RDKY7046 (MATa
hom3–10 ura3D0 leu2D0 trp1D63 his3D200 lyp1::TRP1 cyh2-Q38K
iYFR016C::PMFA1-LEU2 iYEL062W::Ty912-hphNT1 hxt13::URA3). Disruption
of the 43 query genes in RDKY7635 with HIS3 was performed using standard
methods (Supplementary Table 9).
First-generation set of bait strains. The first-generation set of bait strains
(Supplementary Data 1) was primarily obtained from strains present in the
S. cerevisiae deletion collection (Open Biosystems). The mutant strains were chosen
based on the 1,041 genes identified in our in silico screen for candidate GIS genes29
(Supplementary Data 1). Among the 1,041 genes, 46 genes were not included; the
majority of these 46 genes were either essential for viability or sporulation or encoded
TLC1, which is a non-protein-coding gene and therefore not present in the available
deletion collection (Supplementary Data 1). An additional 12 genes were not included
because the 1,041 genes in the in silico screen were finalized after the first-generation
bait strain set was selected (Supplementary Data 1). Mutations in some of the 1,041
candidate GIS genes were not present in the deletion collection and were subsequently
constructed in BY4741, including mec1::G418 sml1::hph, ddc2::G418 sml1::hph,
rad53::G418 sml1::hph, andmrc1-aq.G418. In addition, we constructed a control strain
by replacing leu2D0 present in BY4741 with the G418-resistance marker, which
allows leu2::G418-containing progeny to be selected during systematic mating; these
control strains are labelled as leu2D in the figures. We also added mutations in 60
additional genes associated with pathways implicated by the 1,041 genes identified in
the in silico screen (Supplementary Data 1). We verified all the deletions by PCR
amplification using primers that hybridized within the inserted G418-resistance
cassette and primers that hybridized to flanking sequences. Deletions that could
not be verified were either replaced by crossing a verified BY4742 deletion strain
with BY4741 and sporulating the resulting diploid or by constructing new strains
by PCR-mediated gene disruption in BY4741 when a verified BY4742 strain was
unavailable (Supplementary Table 10). The final first-generation mutation strain
set included 1,058 strains (corresponding to deletions of 1,055 genes of interest
with two additional mrc1 and rad53 alleles and the leu2D control deletion;
Supplementary Data 1).
Second-generation set of bait strains. To facilitate double-mutant strain
production, we divided the first-generation bait strain collection into two groups,
(i) a ‘high-priority’ set (502 strains) and (ii) a ‘low-priority’ set (555 strains;
Supplementary Data 1). The high-priority set contained mutations in GIS genes
and genes with patterns of genetic interactions that were most similar to those of
known GIS genes29 (Supplementary Fig. 13). During the initial construction and
analysis of double-mutant strains, we identified four mutations, dia2D, exo1D,
rrm3D and rtt107D, out of 30 mutations tested at the time, which interacted with
the largest number of bait mutations in the high-priority set, resulting in increased
GCR strain scores. No other set of the final 43 query mutations interacted with
490% of the mutations that the dia2D, exo1D, rrm3D and rtt107D mutations were
found to interact with. We crossed these four mutations to the low-priority set of
mutants and scored the resulting double mutants. These four query mutations
showed genetic interactions with a much lower proportion of the mutations in
the low-priority mutation set compared with the high-priority mutation set
(Supplementary Fig. 14). We then identified mutations in the low-priority set that
(i) increased the GCR strain scores in at least one of the dGCR, sGCR or tyGCR
assay-containing strains (22 mutations), (ii) showed interactions with at least
one of the dia2D, exo1D, rrm3D and rtt107D mutations in the dGCR assay (87
mutations, 9 in common with group (i)), or (iii) could not be evaluated as we
did not recover strains when crossing the wild-type query strains or dGCR
assayþmutant query strains (39 mutations). We then added strains containing
these mutations to the strains containing the high-priority mutations. This resulted
in a second-generation bait strain collection containing 639 strains that were then
crossed to the remainder of the dGCRþ query mutation strains.
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Screen for GCR-suppressing genes and interacting genes. Query strains grown
on YPD-agar were crossed to arrayed strains containing bait mutations on
YPD-agar in quadruplicate by pinning onto a fresh YPD agar plate using a Singer
RoToR robot (Singer Instruments, UK) and grown for 1–2 days at 30 C. The cells
were then subjected to two rounds of pinning onto diploid selection medium (YPD-
agar containing 200mgml 1 geneticin (G418; Gibco) and 100mgml 1 nourseo-
thricin (clonNAT; Werner BioAgents)) and grown for 1–2 days at 30 C. The cells
were then pinned onto presporulation medium (containing 15 g Difco nutrient broth
(Fisher Scientific), 5 g Bacto-yeast extract (Fisher Scientific), 10 g Bacto-agar (Fisher
Scientific) and 62.5ml 40% glucose per 500ml) and grown for 3 days at 30 C. Cells
from the presporulation medium were then pinned onto sporulation medium (10 g
potassium acetate, 0.05 g zinc acetate, 20 g Bacto-agar per liter, containing a final
concentration of 50mgml 1 G418 and 25mgml 1 nourseothricin) and incubated
for 7 days at 30 C. The resulting spore-containing cells were then subjected to two
rounds of pinning onto diploid killing medium (1.7 g yeast nitrogen base without
amino acids and without ammonium sulfate (Fisher Scientific), 1 g L-glutamic acid
monosodium salt (Sigma), 2 g dropout mix34 without uracil, lysine, leucine and, when
appropriate, without histidine, 20 g Bacto-agar, 50ml of 40% glucose per liter,
containing a final concentration of 50mgml 1 thialysine (S-(2-aminoethyl)-L-
cysteine hydrochloride; Sigma), 10mgml 1 cycloheximide, 200mgml 1 G418, and
100mgml 1 nourseothricin) followed by growth for 5 days at 30 C for the first
pinning and 2 days at 30 C for the second pinning. Cells were then subjected to two
rounds of pinning and growth on haploid selection medium (1.7 g yeast nitrogen base
without amino acids and without ammonium sulfate, 1 g L-glutamic acid
monosodium salt, 2 g CSM dropout mix without leucine, uracil and, when
appropriate, without histidine, 20 g Bacto-agar, 50ml of 40% glucose per liter,
containing a final concentration of 200mgml 1 G418 and 100mg/ml nourseothricin)
and grown for 2 days at 30 C. Then the cells were pinned and grown on YPD-agar
followed by storage at  85 C in YPD media containing glycerol.
GCR patch tests. A minimum of three independent spore clones were isolated
from each mutant progeny pool arising from the SGA protocol and then grown as
patches on a YPD-agar plate at 30 C for two days and replica-plated onto
CSM -Arg media containing 60mg l 1 canavanine (Sigma) and 1 g l 1
5-fluoroorotic acid (US Biological). The number of papillae growing on the GCR
medium was scored using a semi-quantitative scoring system as follows: 0, no
papillae; 1, 1–5 papillae (this was on average the number of papillae observed with
the leu2D control strain for the dGCR assay); 2, 6–15 papillae; 3, 16—a countable
number of papillae (B150–200); 4, papillae that were too many or too close
together to count; 5, a lawn of papillae covering the entire patch (Fig. 1d). Then the
scores for all independent patches analysed for each mutant were averaged to
generate a GCR strain score (Supplementary Data 1). Negative scores were assigned
to strains that did not grow so that these strains could be ignored during the
analysis.
Determination of GCR rates. The media and protocol for strain propagation and
measuring GCR rates were as described previously49.
Determination of an optimal cutoff score. Using 101 paired GCR rates and
average GCR patch scores for single mutants in the dGCR assay and 43 strains
resulting from the crosses of mutant dGCR query strains with the leu2D control
strain, we determined an optimal cutoff score as described50. Briefly, for any given
cutoff value, ci, we calculated the sensitivity, which is the fraction of mutations
causing increased GCR rates that we include as SENSi¼TPi /(TPi þ FNi), where
TPi is the number of true positives (mutants with a GCR rate at least threefold
higher than wild-type with a score Zci) and FNi is the number of false negatives
(mutants with a GCR rate at least threefold higher than wild type with a scoreoci).
For each cutoff value, we also calculated the specificity, which is the fraction of
mutants that do not have increased GCR rates that we reject: SPECi¼TNi/
(TNiþ FPi), where TNi is the number of true negatives (mutants with a GCR rate
less than threefold higher than wild-type with a scoreoci) and FPi is the number of
false positives (mutants with a GCR rate less than threefold higher than wild-type
with a score4ci). An optimal cutoff for balancing sensitivity and specificity can be
determined by optimizing the cost function w1SENSi þw2SPECi as a function of ci.
Here we weighted sensitivity slightly higher than specificity (w1¼ 2, w2¼ 1) with
the rationale that false negatives were more problematic because false positives
could be identified by subsequent quantitative rate testing. We found that the
optimal cutoff ci was 1.38 for the set of 101 rate/score pairs solely from the wild-
type dGCR cross and for the set of 144 rate/score pairs from the wild-type dGCR
cross and the leu2 double mutants from the mutant dGCR crosses (Supplementary
Fig. 2). With equal weights, the optimal cutoff was slightly higher, B1.69. As
expected, analysis of Receiver-Operator Characteristic (ROC) curves51 showed that
mutations causing higher GCR rates were clearly better detected by these patch-
based GCR strain scores than mutations that only weakly increased the GCR rates
(Supplementary Fig. 2). We also used the Kolmogorov–Smirnov test as extended
for discrete null distributions as implemented in R52 to calculate P-values for
differences between the distribution of patches from the leu2D control strain and
each single mutant. Unlike calculations based on the average GCR patch score, this
test included the number and distribution of all observed patches. We found that
the list of mutant strains with significantly different patch scores that were higher
than the leu2D control strain (Po0.01) was essentially the same as the list of strains
identified by minimizing the false-positive and false-negative errors as described
above.
Analysis of S. cerevisiae modules. Protein complex and pathway (module)
definitions were extracted from a variety of studies53–60 as well as manually curated
complexes such as CYC2008v2 and YHTP2008 (ref. 61), the Saccharomyces
Genome Database GO complex and pathway definitions62, S. cerevisiae KEGG
pathways63, and S. cerevisiae MetaCyc pathways64. Modules containing genes that
showed increased GCR scores alone or enhanced the GCR scores of query
mutations were identified. Hits were manually curated to identify well-supported
modules, and these modules were divided into two groups. The first group
contained modules with more than one gene that when mutated shared at least one
query mutation that caused increased GCR scores. The second group contained
modules for which only a single gene caused increased GCR interactions when
mutated or for which multiple genes when mutated caused increased GCR
interactions but lack shared interacting partners.
Analysis of cancer genomics data. TCGA data31,32, including expression z-scores,
methylation and GISTIC CNV (copy number variation) data were obtained from the
cBIO portal (http://www.cbioportal.org) through the CGDS-R package. Somatic
mutation data were obtained from a local compilation39 that includes data from
TCGA and COSMIC as well as a compilation of data from the literature. As
previously described39, all mutations for a given tumour were used in the S-score
calculation. For all other analyses, only TCGA mutation data were used. As defined
by TCGA, putative copy-number calls on samples were determined using the
GISTIC algorithm65. Boxplots were generated using ggplot2, a graphics tool for the R
statistical package (http://ggplot2.org). For expression data, the Z-score metrics
adopted by TCGA were used. The data for all tumour samples were categorized in
Excel Spreadsheets using the cut-offs for copy number, expression, methylation and
mutation predictions indicated in the contents of each Supplementary Data
spreadsheet.
Computational prediction of the functional impact of missense mutations. To
identify putative deleterious missense mutations in our gene set, we used five
different computational algorithms resulting in six different tests per mutation:
SIFT66, PolyPhen-2 (ref. 67), MutationTester68, Fathmm69 and LTR70. Two
versions of PolyPhen-2 were used, each one trained by a different dataset (HDIV
and HVAR). Each missense mutation was assigned a score called the ‘Ndamage
score’ that was the number of prediction tests in which the mutation scored as
deleterious. To be considered ‘predicted deleterious’, a given missense mutation
had to have an Ndamage score of 5 or 6.
Simulations to determine statistical significance in cancer genomics analyses.
Two types of simulations were used. First, a gene-set enrichment analysis was per-
formed to evaluate whether the set of GIS genes were enriched with genes with
extreme S-scores (r 2 or Z2). Ten thousand random sets of the same size
(number of genes) were selected from the pool of all human genes, and for each set
the number of genes with extreme S-scores was defined. A P-value for the enrich-
ment analysis was determined by ranking the real set in the random set distribution.
Second, we evaluated whether a given set of genes was enriched for different types of
mutations (or combinations of different types). To avoid any bias due to different
gene lengths, we normalized the analysis for the total length of the corresponding
gene set (in amino acids of the longest coding region for each gene). The total
number of amino acids for the real set was randomly selected from the total pool of
human genes (10,000 random sets). The number of mutations in the real set was
then compared with all random sets, and a P value for the enrichment analysis was
determined by ranking the real set within the distribution of the random sets.
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